NYSE:MDT - Medtronic Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$86.99 +1.73 (+2.03 %)
(As of 05/25/2018 03:15 AM ET)
Previous Close$85.26
Today's Range$86.00 - $88.65
52-Week Range$76.41 - $89.72
Volume8.72 million shs
Average Volume5.30 million shs
Market Capitalization$115.17 billion
P/E Ratio18.91
Dividend Yield2.17%
Beta0.94

About Medtronic (NYSE:MDT)

Medtronic logoMedtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions. The company's Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company's Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:MDT
CUSIP58505510
Phone353-1438-1700

Debt

Debt-to-Equity Ratio0.51
Current Ratio2.43
Quick Ratio2.09

Price-To-Earnings

Trailing P/E Ratio18.91
Forward P/E Ratio18.35
P/E Growth2.33

Sales & Book Value

Annual Sales$29.71 billion
Price / Sales3.97
Cash Flow$6.9704 per share
Price / Cash12.48
Book Value$36.83 per share
Price / Book2.36

Profitability

EPS (Most Recent Fiscal Year)$4.60
Net Income$4.03 billion
Net Margins9.44%
Return on Equity12.65%
Return on Assets6.58%

Miscellaneous

Employees91,000
Outstanding Shares1,355,370,000

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic announced a quarterly dividend on Friday, March 9th. Shareholders of record on Friday, March 23rd will be paid a dividend of $0.46 per share on Friday, April 13th. This represents a $1.84 dividend on an annualized basis and a yield of 2.12%. The ex-dividend date is Thursday, March 22nd. View Medtronic's Dividend History.

How will Medtronic's stock buyback program work?

Medtronic announced that its Board of Directors has authorized a stock repurchase plan on Thursday, October 5th 2017, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 49% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) released its earnings results on Thursday, May, 24th. The medical technology company reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $1.39 by $0.03. The medical technology company had revenue of $8.14 billion for the quarter, compared to analyst estimates of $8 billion. Medtronic had a net margin of 9.44% and a return on equity of 12.65%. The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business earned $1.33 earnings per share. View Medtronic's Earnings History.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic updated its FY19 earnings guidance on Thursday, May, 24th. The company provided earnings per share guidance of $5.10-5.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.14.

What price target have analysts set for MDT?

22 brokers have issued twelve-month target prices for Medtronic's shares. Their predictions range from $80.00 to $99.00. On average, they expect Medtronic's share price to reach $91.6053 in the next year. View Analyst Ratings for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:
  • 1. According to Zacks Investment Research, "Medtronic exited the fiscal second quarter on a mixed note. While the company demonstrated improved segmental performances at CER, escalating costs and expenses continue to weigh on the bottom line. Unfavorable currency translation also acted as a dampener. On the bright side, all major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. The recent receipt of FDA approval and commercial launch of Azure pacemakers with BlueSync technology buoy optimism. Apart from product innovation, the company is focusing on geographical diversification of its businesses. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside." (11/23/2017)
  • 2. Needham & Company LLC analysts commented, "On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model." (11/9/2017)

Who are some of Medtronic's key competitors?

Who are Medtronic's key executives?

Medtronic's management team includes the folowing people:
  • Mr. Omar S. Ishrak, Chairman and Chief Exec. Officer (Age 62)
  • Ms. Karen L. Parkhill, Exec. VP & CFO (Age 53)
  • Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 56)
  • Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 57)
  • Mr. Mark Ploof, Sr. VP of Global Operations & Bus. Services

Has Medtronic been receiving favorable news coverage?

News stories about MDT stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medtronic earned a coverage optimism score of 0.04 on Accern's scale. They also assigned news headlines about the medical technology company an impact score of 46.55 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.08%), Massachusetts Financial Services Co. MA (4.42%), Franklin Resources Inc. (2.65%), Artisan Partners Limited Partnership (1.66%), Northern Trust Corp (1.19%) and Barrow Hanley Mewhinney & Strauss LLC (1.12%). Company insiders that own Medtronic stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic.

Which institutional investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Asset Management One Co. Ltd., Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc., OppenheimerFunds Inc., Swiss National Bank, Massachusetts Financial Services Co. MA and Barrow Hanley Mewhinney & Strauss LLC. Company insiders that have sold Medtronic company stock in the last year include Bryan C Hanson, Carol A Surface, Hooman Hakami, James T Lenehan, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic.

Which institutional investors are buying Medtronic stock?

MDT stock was acquired by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Westwood Holdings Group Inc., BlackRock Inc., Summit Trail Advisors LLC, Wells Fargo & Company MN, Artisan Partners Limited Partnership, OMERS ADMINISTRATION Corp and Neuberger Berman Group LLC. Company insiders that have bought Medtronic stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $86.99.

How big of a company is Medtronic?

Medtronic has a market capitalization of $115.17 billion and generates $29.71 billion in revenue each year. The medical technology company earns $4.03 billion in net income (profit) each year or $4.60 on an earnings per share basis. Medtronic employs 91,000 workers across the globe.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]


MarketBeat Community Rating for Medtronic (MDT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  913 (Vote Outperform)
Underperform Votes:  584 (Vote Underperform)
Total Votes:  1,497
MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Medtronic (NYSE:MDT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
22 Wall Street analysts have issued ratings and price targets for Medtronic in the last 12 months. Their average twelve-month price target is $91.6053, suggesting that the stock has a possible upside of 5.31%. The high price target for MDT is $99.00 and the low price target for MDT is $80.00. There are currently 5 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.772.732.702.57
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $91.6053$91.2368$91.50$88.50
Price Target Upside: 5.31% upside16.28% upside12.70% upside7.48% upside

Medtronic (NYSE:MDT) Consensus Price Target History

Price Target History for Medtronic (NYSE:MDT)

Medtronic (NYSE:MDT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2018OppenheimerReiterated RatingBuyMediumView Rating Details
5/21/2018SunTrust BanksBoost Price TargetBuy$96.00LowView Rating Details
4/27/2018Piper Jaffray CompaniesInitiated CoverageOverweight$90.00MediumView Rating Details
3/29/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$95.00 ➝ $90.00MediumView Rating Details
2/22/2018CitigroupReiterated RatingBuy ➝ Buy$100.00 ➝ $93.00LowView Rating Details
2/14/2018Royal Bank of CanadaReiterated RatingOutperform$92.00MediumView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$92.50HighView Rating Details
1/2/2018Bank of AmericaUpgradeNeutral ➝ BuyHighView Rating Details
12/12/2017ArgusUpgradeHold ➝ Buy$81.27 ➝ $95.00LowView Rating Details
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$94.00LowView Rating Details
11/23/2017Jefferies GroupReiterated RatingBuy$99.00N/AView Rating Details
11/22/2017Northland SecuritiesReiterated RatingHold$80.00N/AView Rating Details
11/22/2017Stifel NicolausBoost Price TargetHold$83.00 ➝ $85.00N/AView Rating Details
11/9/2017Needham & Company LLCReiterated RatingBuy$94.00N/AView Rating Details
11/3/2017CowenReiterated RatingBuy$95.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingMarket Perform$88.00 ➝ $85.00N/AView Rating Details
10/9/2017Wells Fargo & CoDowngradeOutperform ➝ Market Perform$93.00 ➝ $83.00N/AView Rating Details
8/24/2017UBSReiterated RatingOverweightLowView Rating Details
8/23/2017BarclaysLower Price TargetOverweight$94.00 ➝ $92.00LowView Rating Details
7/31/2017Deutsche BankSet Price TargetBuy$96.00LowView Rating Details
7/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
5/26/2017CIBCReiterated RatingBuyLowView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$87.00LowView Rating Details
3/20/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
2/22/2017WedbushReiterated RatingNeutral$85.00N/AView Rating Details
1/3/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$84.00 ➝ $79.00N/AView Rating Details
8/25/2016Credit Suisse GroupReiterated RatingOutperform$92.00N/AView Rating Details
6/8/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Medtronic (NYSE:MDT) Earnings History and Estimates Chart

Earnings by Quarter for Medtronic (NYSE:MDT)

Medtronic (NYSE:MDT) Earnings Estimates

2018 EPS Consensus Estimate: $4.71
2019 EPS Consensus Estimate: $5.16
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20186$1.07$1.15$1.10
Q2 20187$0.89$1.20$1.03
Q3 20187$1.15$1.24$1.18
Q4 20187$1.38$1.46$1.40
Q1 20194$1.12$1.22$1.18
Q2 20194$1.17$1.21$1.19
Q3 20194$1.26$1.32$1.29
Q4 20194$1.46$1.53$1.51

Medtronic (NYSE MDT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/21/2018N/AView Earnings Details
5/24/20184/30/2018$1.39$1.42$7.9992 billion$8.1440 billionViewN/AView Earnings Details
2/20/2018Q3 18$1.16$1.17$7.2012 billion$7.3690 billionViewListenView Earnings Details
11/21/2017Q2 18$0.99$1.07$7.0493 billion$7.05 billionViewN/AView Earnings Details
8/22/20177/31/2017$1.08$1.12$7.4441 billion$7.39 billionViewN/AView Earnings Details
5/25/2017Q4 17$1.31$1.33$7.8602 billion$7.9160 billionViewN/AView Earnings Details
2/21/20171/31/2017$1.11$1.12$7.2171 billion$7.2830 billionViewListenView Earnings Details
11/22/2016Q217$1.11$1.12$7.46 billion$7.35 billionViewListenView Earnings Details
8/25/2016Q117$1.01$1.03$7.1694 billion$7.20 billionViewListenView Earnings Details
5/31/2016Q416$1.26$1.27$7.49 billion$7.57 billionViewListenView Earnings Details
3/1/2016Q316$1.06$1.06$6.99 billion$6.93 billionViewListenView Earnings Details
12/3/2015Q216$1.00$1.03$7.0754 billion$7.0580 billionViewListenView Earnings Details
9/3/2015Q116$1.01$1.02$7.0291 billion$7.2740 billionViewListenView Earnings Details
6/2/2015Q415$1.11$1.16$7.1771 billion$7.30 billionViewListenView Earnings Details
2/17/2015Q3$0.97$1.01$4.25 million$4.32 millionViewListenView Earnings Details
11/18/2014Q2$0.96$0.96$4.37 million$4.40 millionViewListenView Earnings Details
8/19/2014Q115$0.92$0.93$4.25 billion$4.27 billionViewListenView Earnings Details
5/20/2014Q414$1.12$1.12$4.58 billion$4.60 billionViewListenView Earnings Details
2/18/2014Q314$0.91$0.91$4.15 billion$4.20 billionViewListenView Earnings Details
11/19/2013Q214$0.90$0.91$4.18 billion$4.20 billionViewListenView Earnings Details
8/20/2013Q1 2014$0.88$0.88$4.11 billion$4.10 billionViewListenView Earnings Details
5/21/2013Q4 2013$1.03$1.10$4.39 billion$4.50 billionViewListenView Earnings Details
2/19/2013Q3 2013$0.91$0.93$4.03 billion$4.03 billionViewListenView Earnings Details
11/20/20120.88$0.88$4.10 billionViewN/AView Earnings Details
8/21/2012$0.85$0.85ViewN/AView Earnings Details
5/22/2012$0.98$0.99ViewN/AView Earnings Details
2/21/2012$0.84$0.88ViewN/AView Earnings Details
11/22/2011$0.82$0.84ViewN/AView Earnings Details
8/23/2011$0.79$0.79ViewN/AView Earnings Details
5/24/2011$0.93$0.90ViewN/AView Earnings Details
2/22/2011$0.84$0.86ViewN/AView Earnings Details
11/23/2010Q2 2011$0.81$0.82ViewN/AView Earnings Details
8/24/2010Q1 2011$0.82$0.80ViewN/AView Earnings Details
5/25/2010Q4 2010$0.88$0.89ViewN/AView Earnings Details
2/23/2010Q3 2010$0.76$0.77ViewN/AView Earnings Details
11/24/2009Q2 2010$0.74$0.77ViewN/AView Earnings Details
8/25/2009Q1 2010$0.78$0.79ViewN/AView Earnings Details
5/19/2009Q4 2009$0.82$0.82ViewN/AView Earnings Details
2/17/2009Q3 2009$0.71$0.71ViewN/AView Earnings Details
11/18/2008Q2 2009$0.71$0.67ViewN/AView Earnings Details
8/19/2008Q1 2009$0.69$0.72ViewN/AView Earnings Details
5/20/2008Q4 2008$0.73$0.78ViewN/AView Earnings Details
2/19/2008Q3 2008$0.61$0.63ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Medtronic (NYSE:MDT) Dividend Information

Medtronic pays an annual dividend of $1.84 per share, with a dividend yield of 2.12%. MDT's most recent quarterly dividend payment was Friday, April 13. The company has grown its dividend for the last 40 consecutive years and is increasing its dividend by an average of 15.00% each year. Medtronic pays out 40.00% of its earnings out as a dividend.
Most Recent Dividend:4/13/2018
Annual Dividend:$1.84
Dividend Yield:2.12%
Dividend Growth:15.00% (3 Year Average)
Payout Ratio(s):40.00% (Trailing 12 Months of Earnings)
38.82% (Based on This Year's Estimates)
35.73% (Based on Next Year's Estimates)
26.40% (Based on Cash Flow)
Track Record:40 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Medtronic (NYSE:MDT)

Medtronic (NYSE:MDT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/9/2018Quarterly$0.462.2%3/22/20183/23/20184/13/2018
12/8/2017Quarterly$0.4612/28/201712/29/20171/19/2018
8/28/2017Quarterly$0.462.31%9/28/20179/29/201710/20/2017
6/23/2017Quarterly$0.462.07%7/5/20177/7/20177/26/2017
3/10/2017Quarterly$0.432.08%3/22/20173/24/20174/13/2017
12/9/2016quarterly$0.432.33%12/21/201612/23/20161/13/2017
8/22/2016Quarterly$0.431.98%9/27/20169/29/201610/21/2016
6/24/2016quarterly$0.431.85%7/6/20167/8/20167/27/2016
2/22/2016quarterly$0.381.98%3/22/20163/24/20164/15/2016
12/11/2015quarterly$0.381.96%12/22/201512/24/20151/15/2016
8/21/2015quarterly$0.382.18%9/23/20159/25/201510/16/2015
6/19/2015quarterly$0.381.97%6/25/20156/29/20157/17/2015
2/20/2015quarterly$0.30501.55%3/26/20153/30/20154/17/2015
12/4/2014$0.305012/30/20141/2/20151/16/2015
12/5/2014quarterly$0.30501.63%12/30/20141/2/20151/6/2015
8/21/2014quarterly$0.30501.92%10/1/201410/3/201410/24/2014
6/16/2014quarterly$0.30501.98%7/1/20147/3/20147/25/2014
2/14/2014quarterly$0.281.97%4/2/20144/4/20144/25/2014
12/5/2013quarterly$0.281.93%12/31/20131/3/20141/24/2014
8/22/2013quarterly$0.282.12%10/2/201310/4/201310/25/2013
6/21/2013quarterly$0.282.13%7/2/20137/5/20137/26/2013
2/15/2013quarterly$0.262.21%4/3/20134/5/20134/26/2013
12/9/2012quarterly$0.262.44%12/13/201212/17/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Medtronic (NYSE MDT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 80.37%
Insider Trading History for Medtronic (NYSE:MDT)
Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Medtronic (NYSE MDT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018James T. LenehanDirectorSell1,306$83.56$109,129.36View SEC Filing  
3/5/2018Carol A SurfaceSVPSell24,479$78.18$1,913,768.22View SEC Filing  
1/9/2018Richard KuntzVPSell78,526$86.21$6,769,726.46149,761View SEC Filing  
1/5/2018Hooman HakamiEVPSell26,158$85.00$2,223,430.00View SEC Filing  
12/15/2017Bryan C HansonEVPSell16,000$82.82$1,325,120.0088,818View SEC Filing  
11/16/2017Bryan C. HansonEVPSell16,000$79.02$1,264,320.00View SEC Filing  
10/16/2017Bryan C HansonEVPSell16,000$78.03$1,248,480.00View SEC Filing  
9/15/2017Omar IshrakCEOSell140,407$81.63$11,461,423.41668,503View SEC Filing  
7/17/2017Bryan C. HansonEVPSell12,000$88.57$1,062,840.00View SEC Filing  
6/21/2017Richard H AndersonDirectorBuy5,600$88.90$497,840.0071,910View SEC Filing  
3/20/2017Hoedt Rob TenEVPSell50,757$81.58$4,140,756.0659,392View SEC Filing  
3/15/2017Omar IshrakCEOSell95,000$82.82$7,867,900.00645,616View SEC Filing  
3/2/2017Hooman HakamiEVPSell52,316$82.33$4,307,176.2873,800View SEC Filing  
12/13/2016Robert C. PozenDirectorBuy13,660$73.21$1,000,048.60View SEC Filing  
11/23/2016James T. LenehanDirectorBuy2,000$73.27$146,540.00View SEC Filing  
9/27/2016Richard KuntzVPSell17,141$86.70$1,486,124.70149,425View SEC Filing  
9/26/2016Richard KuntzVPSell25,199$86.67$2,183,997.33149,425View SEC Filing  
9/15/2016Kendall J. PowellDirectorSell7,907$85.45$675,653.15View SEC Filing  
9/15/2016Omar IshrakCEOSell61,925$84.93$5,259,290.25565,916View SEC Filing  
8/29/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00168,192View SEC Filing  
7/26/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00108,717View SEC Filing  
7/15/2016Geoffrey MarthaEVPSell3,766$88.26$332,387.16View SEC Filing  
7/13/2016Gary Lee EllisEVPSell35,495$88.64$3,146,276.80View SEC Filing  
7/13/2016Shirley A JacksonDirectorSell2,104$88.64$186,498.5634,503View SEC Filing  
7/6/2016Carol A. SurfaceSVPSell9,787$87.08$852,251.96View SEC Filing  
7/5/2016Bryan C. HansonEVPSell15,272$87.11$1,330,343.92View SEC Filing  
6/3/2016Richard KuntzVPSell49,905$82.60$4,122,153.00127,647View SEC Filing  
4/1/2016Richard KuntzVPSell4,000$75.22$300,880.00104,358View SEC Filing  
3/18/2016Shirley A JacksonDirectorSell1,238$75.60$93,592.8029,812View SEC Filing  
3/17/2016Omar IshrakCEOSell23,799$76.15$1,812,293.85601,838View SEC Filing  
3/4/2016Bryan C HansonEVPSell5,000$75.00$375,000.0096,806View SEC Filing  
2/5/2016Bryan C. HansonEVPSell5,000$76.14$380,700.00View SEC Filing  
1/8/2016Bryan C HansonEVPSell5,000$75.00$375,000.00106,514View SEC Filing  
12/4/2015Richard KuntzVPSell13,715$78.06$1,070,592.90108,086View SEC Filing  
9/15/2015Omar IshrakCEOSell20,000$69.43$1,388,600.00526,824View SEC Filing  
7/14/2015Carol A SurfaceSVPSell13,722$75.83$1,040,539.26View SEC Filing  
4/6/2015Richard KuntzVPSell31,768$77.39$2,458,525.52View SEC Filing  
3/25/2015Gary Lee EllisCFOSell43,183$77.81$3,360,069.23View SEC Filing  
3/13/2015Omar IshrakCEOSell20,000$76.24$1,524,800.00View SEC Filing  
2/19/2015Christopher J OconnellEVPSell50,361$78.22$3,939,237.42View SEC Filing  
12/19/2014Richard KuntzVPSell12,855$74.54$958,211.70View SEC Filing  
12/2/2014Shirley A JacksonDirectorSell1,102$74.43$82,021.86View SEC Filing  
11/28/2014Christopher J OconnellEVPSell42,921$73.95$3,174,007.95View SEC Filing  
10/6/2014Christopher J OconnellEVPSell15,388$64.98$999,912.24View SEC Filing  
8/26/2014Christopher J OconnellEVPSell28,000$63.57$1,779,960.00View SEC Filing  
8/26/2014Shirley A JacksonDirectorSell2,769$63.66$176,274.54View SEC Filing  
4/17/2014Catherine SzymanVPSell29,420$58.79$1,729,601.8021,602View SEC Filing  
4/9/2014Richard KuntzVPSell2,512$60.98$153,181.76104,736View SEC Filing  
4/1/2014Gary Lee EllisCFOSell4,246$61.48$261,044.08174,955View SEC Filing  
3/28/2014Christopher OconnellEVPSell1,982$60.39$119,692.98120,652View SEC Filing  
3/20/2014Catherine SzymanVPSell14,979$59.57$892,299.0321,542View SEC Filing  
3/14/2014Omar IshrakCEOSell10,000$59.12$591,200.00607,192View SEC Filing  
3/10/2014Neil AyotteVPSell1,845$59.64$110,035.8010,782View SEC Filing  
12/4/2013Neil AyotteVPSell1,729$57.14$98,795.0610,850View SEC Filing  
9/13/2013Omar IshrakCEOSell10,000$53.58$535,800.00611,713View SEC Filing  
8/26/2013Catherine SzymanVPSell56,998$52.60$2,998,094.8021,217View SEC Filing  
8/22/2013H James DallasVPSell32,332$53.19$1,719,739.0859,141View SEC Filing  
8/21/2013H James DallasVPSell36,256$52.82$1,915,041.9291,473View SEC Filing  
8/21/2013Shirley JacksonDirectorSell8,033$52.84$424,463.7224,943View SEC Filing  
7/11/2013Christopher J OconnellEVPSell30,429$52.92$1,610,302.68View SEC Filing  
7/11/2013Gary Lee EllisCFOSell32,602$53.62$1,748,119.24View SEC Filing  
7/11/2013H James DallasVPSell69,889$53.72$3,754,437.08View SEC Filing  
7/1/2013H James DallasVPSell20,579$52.10$1,072,165.90View SEC Filing  
6/26/2013D Cameron FindlayVPSell75,042$52.20$3,917,192.40View SEC Filing  
6/19/2013H James DallasVPSell94,117$52.74$4,963,730.58View SEC Filing  
5/22/2013Richard H AndersonDirectorBuy4,800$52.32$251,136.00View SEC Filing  
5/10/2013Jack W SchulerDirectorSell34,230$48.24$1,651,255.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Medtronic (NYSE MDT) News Headlines

Source:
DateHeadline
Medtronics earnings beat estimates as sales of diabetes and heart devices riseMedtronic's earnings beat estimates as sales of diabetes and heart devices rise
www.bizjournals.com - May 24 at 5:30 PM
Medtronic (MDT) Tops Q4 EPS by 3c, Offers FY19 GuidanceMedtronic (MDT) Tops Q4 EPS by 3c, Offers FY19 Guidance
www.streetinsider.com - May 24 at 5:30 PM
Medtronic plc (MDT) Q4 2018 Earnings Conference Call TranscriptMedtronic plc (MDT) Q4 2018 Earnings Conference Call Transcript
www.msn.com - May 24 at 5:30 PM
Medtronic (MDT) Earns Buy Rating from OppenheimerMedtronic (MDT) Earns Buy Rating from Oppenheimer
www.americanbankingnews.com - May 24 at 3:11 PM
Medtronic (MDT) Releases Quarterly  Earnings ResultsMedtronic (MDT) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 24 at 11:28 AM
3 Pros, 3 Cons to Buying Medtronic PLC Stock3 Pros, 3 Cons to Buying Medtronic PLC Stock
investorplace.com - May 24 at 11:18 AM
Critical Survey: Medtronic (MDT) and LivaNova (LIVN)Critical Survey: Medtronic (MDT) and LivaNova (LIVN)
www.americanbankingnews.com - May 24 at 10:19 AM
Medtronic (MDT) Issues FY19 Earnings GuidanceMedtronic (MDT) Issues FY19 Earnings Guidance
www.americanbankingnews.com - May 24 at 8:54 AM
Heart, diabetes devices pump up Medtronics quarterly profitHeart, diabetes devices pump up Medtronic's quarterly profit
www.reuters.com - May 24 at 8:31 AM
Medtronic beats by $0.03, beats on revenueMedtronic beats by $0.03, beats on revenue
seekingalpha.com - May 24 at 8:31 AM
Medtronic plc: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial ResultsMedtronic plc: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
www.finanznachrichten.de - May 24 at 8:31 AM
Medical device maker Medtronic reports 25.5 percent rise in profitMedical device maker Medtronic reports 25.5 percent rise in profit
www.reuters.com - May 24 at 8:31 AM
Medtronic: Fiscal 4Q Earnings SnapshotMedtronic: Fiscal 4Q Earnings Snapshot
finance.yahoo.com - May 24 at 8:31 AM
Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial ResultsMedtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
finance.yahoo.com - May 24 at 8:31 AM
Medtronic Q4 revenues up 3%; non-GAAP EPS up 7%; updates guidanceMedtronic Q4 revenues up 3%; non-GAAP EPS up 7%; updates guidance
seekingalpha.com - May 24 at 8:31 AM
Medtronic profit beats estimates fueled by demand for heart valves, insulin pumpsMedtronic profit beats estimates fueled by demand for heart valves, insulin pumps
finance.yahoo.com - May 24 at 8:31 AM
Medtronic (MDT) call put ratio 1.5 calls to 1 put into Q4Medtronic (MDT) call put ratio 1.5 calls to 1 put into Q4
www.streetinsider.com - May 23 at 5:24 PM
BRIEF-New Medtronic data shows blood pressure lowering effect of renal denervationBRIEF-New Medtronic data shows blood pressure lowering effect of renal denervation
www.reuters.com - May 23 at 8:00 AM
New Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti ...New Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti ...
globenewswire.com - May 23 at 8:00 AM
New Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti-Hypertensive MedicationNew Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti-Hypertensive Medication
finance.yahoo.com - May 23 at 8:00 AM
SunTrust Banks Weighs in on Medtronic PLCs Q4 2018 Earnings (MDT)SunTrust Banks Weighs in on Medtronic PLC's Q4 2018 Earnings (MDT)
www.americanbankingnews.com - May 23 at 7:14 AM
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?
finance.yahoo.com - May 22 at 5:25 PM
Medtronic PLC Forecasted to Earn Q1 2019 Earnings of $1.18 Per Share (MDT)Medtronic PLC Forecasted to Earn Q1 2019 Earnings of $1.18 Per Share (MDT)
www.americanbankingnews.com - May 22 at 7:48 AM
Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
finance.yahoo.com - May 21 at 5:24 PM
Medtronic (MDT) PT Raised to $96.00 at SunTrust BanksMedtronic (MDT) PT Raised to $96.00 at SunTrust Banks
www.americanbankingnews.com - May 21 at 10:54 AM
Will Strong RTG Arm Drive Medtronics (MDT) Q4 Earnings?Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
www.zacks.com - May 21 at 8:39 AM
 Analysts Anticipate Medtronic PLC (MDT) Will Post Quarterly Sales of $7.99 Billion Analysts Anticipate Medtronic PLC (MDT) Will Post Quarterly Sales of $7.99 Billion
www.americanbankingnews.com - May 21 at 4:57 AM
Medtronic PLC (MDT) Expected to Post Earnings of $1.38 Per ShareMedtronic PLC (MDT) Expected to Post Earnings of $1.38 Per Share
www.americanbankingnews.com - May 19 at 3:20 AM
Medtronic Announces 2018 Institutional Investor and Analyst Meeting and WebcastMedtronic Announces 2018 Institutional Investor and Analyst Meeting and Webcast
finance.yahoo.com - May 18 at 5:25 PM
Will Medtronic (MDT) Q4 Earnings Show Growth in All Lines?Will Medtronic (MDT) Q4 Earnings Show Growth in All Lines?
www.zacks.com - May 18 at 9:37 AM
Medtronic (MDT) to Release Quarterly Earnings on ThursdayMedtronic (MDT) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 17 at 1:16 AM
Medtronic (MDT) Launches US Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients ...Medtronic (MDT) Launches US Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients ...
www.streetinsider.com - May 16 at 5:30 PM
Medtronic Begins US Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with ...Medtronic Begins US Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with ...
globenewswire.com - May 16 at 5:30 PM
BRIEF-Medtronic Begins US Study To Evaluate Treatment Of Bifurcation Lesions In Patients With Coronary Artery ...BRIEF-Medtronic Begins US Study To Evaluate Treatment Of Bifurcation Lesions In Patients With Coronary Artery ...
www.reuters.com - May 16 at 5:30 PM
Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery DiseaseMedtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease
finance.yahoo.com - May 16 at 5:30 PM
Detailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos ...Detailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos ...
globenewswire.com - May 16 at 8:59 AM
Detailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos Defense & Security Solutions, and Envision Healthcare — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos Defense & Security Solutions, and Envision Healthcare — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - May 16 at 8:59 AM
Mazor Robotics Starts Its "Transition" Year StrongMazor Robotics Starts Its "Transition" Year Strong
www.fool.com - May 15 at 5:23 PM
Medtronic (MDT) Highlights New Analysis Showing Cardiac Resynchronization Therapy Feature Associated with ...Medtronic (MDT) Highlights New Analysis Showing Cardiac Resynchronization Therapy Feature Associated with ...
www.streetinsider.com - May 15 at 5:23 PM
Mazor Robotics Starts Its "Transition" Year StrongMazor Robotics Starts Its "Transition" Year Strong
finance.yahoo.com - May 15 at 5:23 PM
Estimating The Intrinsic Value Of Medtronic plc (NYSE:MDT)Estimating The Intrinsic Value Of Medtronic plc (NYSE:MDT)
finance.yahoo.com - May 15 at 8:25 AM
New Study Demonstrates Feasibility of Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System to ...New Study Demonstrates Feasibility of Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System to ...
globenewswire.com - May 11 at 5:42 PM
New Study Demonstrates Feasibility of Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System to Detect Atrial Contractions and Restore AV SynchronyNew Study Demonstrates Feasibility of Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System to Detect Atrial Contractions and Restore AV Synchrony
finance.yahoo.com - May 11 at 5:42 PM
Medtronic Study Confirms Feasibility of New Extravascular Approach to ICD TherapyMedtronic Study Confirms Feasibility of New Extravascular Approach to ICD Therapy
finance.yahoo.com - May 11 at 5:42 PM
Medtronic (MDT) Receives Consensus Recommendation of "Buy" from BrokeragesMedtronic (MDT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 10 at 5:45 PM
Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2018Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2018
finance.yahoo.com - May 10 at 5:22 PM
Heres How Medtronic Can Unlock Shareholder Value, Says AnalystHere's How Medtronic Can Unlock Shareholder Value, Says Analyst
www.thestreet.com - May 9 at 8:31 AM
A Look at Abbott Laboratories’ Valuation MultiplesA Look at Abbott Laboratories’ Valuation Multiples
finance.yahoo.com - May 8 at 8:33 AM
Today’s Research Reports on Stocks to Watch: Tetraphase Pharmaceuticals and MedtronicToday’s Research Reports on Stocks to Watch: Tetraphase Pharmaceuticals and Medtronic
finance.yahoo.com - May 8 at 8:33 AM
Medtronic Hires JPMorgan Analyst, and Investors Rate It a BuyMedtronic Hires JPMorgan Analyst, and Investors Rate It a 'Buy'
www.bloomberg.com - May 7 at 5:24 PM

SEC Filings

Medtronic (NYSE:MDT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Medtronic (NYSE:MDT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Medtronic (NYSE MDT) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.